On October 16, 2026 Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, reported that the Company will participate in the Chardan Healthcare Conference taking place in New York City on October 20, 2026.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On Tuesday, October 20, 2026, at 2:00 p.m. ET, Peggy Scherle, Ph.D., Chief Scientific Officer of Prelude and Bryant Lim, Chief Financial Officer, will participate in a fireside chat.

A live webcast of the fireside chat can be accessed on the Company’s website under Events and Presentations. The recording will be archived and available on the Company’s website for 90 days.

(Press release, Prelude Therapeutics, OCT 16, 2026, View Source [SID1234673533])

On October 16, 2026 Shenzhen Chipscreen Biosciences Co., Ltd. ("Chipscreen Biosciences") (SSE: 688321) reported that NW001, a first-in-class epigenetic immune-modulating antibody conjugate (EIMAC) co-developed with Chengdu Chipscreen Newway Biosciences Co., Ltd., has obtained IND approval from China’s National Medical Products Administration (NMPA). The Phase 1 trial will assess the safety, tolerability, pharmacokinetics and preliminary antitumor activity of NW001 in patients with advanced tumors.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Although immune checkpoint inhibitors have reshaped the treatment landscape for many advanced cancers, immunologically "cold" tumors and primary or acquired resistance remain major clinical challenges. Improving the efficacy of immunotherapy and overcoming resistance are therefore key priorities in developing next-generation immuno-oncology (IO) drugs.

NW001 is an epigenetic immune-modulating antibody conjugate (EIMAC). Its antibody component is a humanized anti-PD-L1 monoclonal antibody, conjugated to a novel histone deacetylase inhibitor (HDACi) payload. Upon binding to cell-surface PD-L1, NW001 is internalized and undergoes intracellular cleavage, releasing the HDACi payload to exert antitumor activity through combined epigenetic and immune modulation. This design aims to enable precise release of the epigenetic modulator payload inside tumor cells and reduce systemic exposure. It has the potential to overcome limitations of current immunotherapies and marks a key milestone in Chipscreen Biosciences’ IO 2.0 strategy.

Preclinical studies show that NW001 exhibits marked antitumor activity in models refractory or resistant to PD-1/PD-L1 inhibitors. In responsive models, it also demonstrates greater antitumor activity than that of PD-L1 inhibitors. NW001 shows favorable pharmacokinetic properties and is well tolerated in non-human primates.

Through its work on chidamide, the world’s first approved oral, subtype-selective HDAC inhibitor, the company has extensively explored the interplay between epigenetics and tumor immunology, accumulating substantial preclinical and clinical evidence. The combination of chidamide and immune checkpoint inhibitors has met the primary efficacy endpoint in a global Phase 3 study in melanoma. A Phase 3 study in colorectal cancer conducted in China has completed patient enrollment.

Built on the clinically validated epigenetic immune-modulating mechanism, NW001 is designed to widen the therapeutic window; it therefore has the potential to offer superior efficacy to that of current immunotherapies, and to overcome treatment limitations in immunologically "cold" tumors and tumors resistant to immunotherapy.

(Press release, Shenzhen Chipscreen Biosciences, OCT 16, 2026, View Source [SID1234673532])

On October 16, 2026 Cofactor Genomics reported publication of its OncoPrism-NSCLC clinical validation study in npj Precision Oncology, a peer-reviewed Nature Portfolio journal. The study represents the latest results from Cofactor’s multisite PREDAPT clinical trial and extends the clinical validation of the multidimensional RNA biomarker underlying OncoPrism-HNSCC—a clinically validated, Medicare-covered test for recurrent or metastatic head and neck squamous cell carcinoma—to advance precision oncology in non-small cell lung cancer (NSCLC). This study represents a significant milestone in cancer care given NSCLC represents the largest U.S. patient population eligible for immune checkpoint inhibitor therapy.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The study demonstrated that the same biomarker underlying OncoPrism-HNSCC is represented across five additional cancer types beyond HNSCC: NSCLC, clear cell renal cell carcinoma, colon adenocarcinoma, triple-negative breast cancer, and bladder carcinoma. Building on this cross-cancer analysis, PREDAPT investigators across 17 US Health Care systems calibrated the test specifically for NSCLC and performed in-depth clinical validation against treatment response and survival outcomes. The study found high-scoring OncoPrism-NSCLC patients were significantly more likely to respond to immune checkpoint inhibitors and had significantly longer survival, with median overall survival doubled compared to the rest of the population. Importantly, the authors found that OncoPrism-NSCLC is predictive of immune checkpoint inhibitor response specifically, as it was not prognostic in patients treated with chemotherapy or other treatments.

"Precision medicine is not just about finding a target. It is about prioritizing treatment selection based on a patient’s current condition and presence of actionable biomarkers," said Dr. Howard Bailey, Chief Medical Officer of Cofactor Genomics. "This work represents an emerging approach to immunotherapy diagnostics: integrating RNA signals from the tumor-immune microenvironment into a clinically validated prediction, rather than asking a single marker, like PD-L1 expression, to represent a complex biological response."

The publication also suggests using OncoPrism alongside PD-L1, regardless of PD-L1 score. While PD-L1 was not significantly predictive in this study, it is widely used. Among patients whose tumors already had high PD-L1 expression (TPS ≥50%), patients categorized as OncoPrism high had significantly longer progression-free and overall survival. This additional stratification supports further evaluation of complementary testing, rather than treating the two biomarkers as interchangeable. Extending clinical validation from head and neck cancer to NSCLC advances a path beyond reliance on a single protein measurement toward multidimensional RNA models that provide predictive information, particularly when PD-L1 expression alone is insufficient to guide treatment selection.

(Press release, Cofactor Genomics, OCT 16, 2026, View Source [SID1234673531])

On October 16, 2026 Starton Therapeutics Inc. ("Starton"), a clinical-stage biotechnology company employing standard-of-care therapies with proprietary delivery technologies, reported that Chief Medical Officer Dr. Jamie Oliver, Pharm.D., will participate as a panelist at BioFuture 2026, taking place Oct. 27-28, 2026, in New York.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Dr. Oliver will join fellow industry leaders to discuss the technologies shaping what comes next across the life sciences, including oncology, CNS, metabolic disease and diagnostics. Details for the event are as follows:

BioFuture 2026

Location: Cure, 345 Park Avenue South, 12th Floor, New York, NY
Session: Spotlight Panel 1A
Panel Title: BioFuture Now: Breakthroughs Shaping the Next Era of Biopharma Trailblazers
Date: Tuesday, Oct. 27, 2026
Time: 10:00-10:55 a.m. ET

To learn more about the event, please visit www.biofuture.com/.

(Press release, Starton Therapeutics, OCT 16, 2026, View Source [SID1234673530])

On October 16, 2026 Myosin Therapeutics reported that, following its selection as a 2026–2027 National Cancer Institute (NCI) SBIR Investor Initiatives Showcase Company, it has been invited to present at BioFuture 2026, taking place October 27–28 in New York City. Courtney Miller, PhD, Chief Executive Officer, will participate on October 27 in the panel "Beyond the Cure: The Brave New World of Revolutionary Cancer Therapeutics," joining biotechnology leaders exploring emerging approaches in oncology, including next-generation cell therapies, AI-enabled cancer drug discovery, precision medicines and advanced therapeutic platforms. Karen Smith, MD, PhD, MBA, LLM, Chief Medical Officer, will join Dr. Miller for investor and strategic partner meetings throughout the conference.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The panel will feature participating biotechnology CEOs introducing their companies and approaches to oncology, followed by a moderated round-robin discussion examining how emerging technologies and therapeutic strategies are reshaping cancer treatment. The BioFuture invitation follows Myosin’s recent presentations at Biocom California’s Global Partnering & Investor Conference, the BIO Investor Forum and BioFlorida’s South Florida Life Sciences Showcase.

"Glioblastoma is the proving ground for a new way to treat cancer, selectively preventing the physical mechanics tumor cells depend on to grow and survive, rather than targeting signaling pathways that tumors learn to bypass," said Dr. Miller. "With STAR-GBM advancing toward its Phase 2 dose expansion stage, BioFuture comes at the right time to meet the investors and pharmaceutical partners who can help support our planned extension of MT-125 into two additional treatment-resistant cancers."

Myosin Therapeutics is advancing MT-125, a first-in-class non-muscle myosin inhibitor designed to disrupt fundamental mechanical dependencies of cancer cells, leading to tumor cell death. MT-125 has received FDA Orphan Drug Designation for malignant gliomas and FDA Fast Track Designation for glioblastoma (GBM), and the company’s science is supported by two peer-reviewed publications in Cell. The NCI-supported STAR-GBM trial (NCT07185880) is enrolling patients with newly diagnosed, MGMT unmethylated GBM at Mayo Clinic sites in Florida, Arizona and Minnesota.

(Press release, Myosin Therapeutics, OCT 16, 2026, View Source [SID1234673529])